{"title":"Cost-effectiveness analyses of 20-valent pneumococcal conjugate vaccine in children and adults: A narrative review.","authors":"Aiko Shono, Shu-Ling Hoshi, Masahide Kondo","doi":"10.1080/21645515.2025.2525619","DOIUrl":null,"url":null,"abstract":"<p><p>Many pneumococcal vaccines have been developed. Economic evaluation provides a framework to inform decision-making. Cost-effectiveness analysis (CEA) studies on 20-valent pneumococcal conjugate vaccine (PCV20) have been published. We introduce the concept of health economics and the basic framework for CEAs. We present a narrative literature review of recent CEA studies involving the PCV20. We also provide guidance for interpreting vaccine-related CEAs. We included 26 CEAs (17 in adults, nine in children) from 15 countries in this review. Eight of the pediatric studies and 11 of the adult studies concluded that PCV20 strategy would be cost-saving compared with existing vaccine(s), in at least one comparison. CEA is a modeling method based on existing data but includes a degree of uncertainty. It is therefore important to interpret the results of a CEA study with an understanding of the features and limitations of the analysis.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2525619"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269694/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2025.2525619","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Many pneumococcal vaccines have been developed. Economic evaluation provides a framework to inform decision-making. Cost-effectiveness analysis (CEA) studies on 20-valent pneumococcal conjugate vaccine (PCV20) have been published. We introduce the concept of health economics and the basic framework for CEAs. We present a narrative literature review of recent CEA studies involving the PCV20. We also provide guidance for interpreting vaccine-related CEAs. We included 26 CEAs (17 in adults, nine in children) from 15 countries in this review. Eight of the pediatric studies and 11 of the adult studies concluded that PCV20 strategy would be cost-saving compared with existing vaccine(s), in at least one comparison. CEA is a modeling method based on existing data but includes a degree of uncertainty. It is therefore important to interpret the results of a CEA study with an understanding of the features and limitations of the analysis.
期刊介绍：
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
